Since Fernando De Ritis first described AST/ALT ratio as an enzymatic test for viral hepatitis in 1957 [14], researchers have taken it as a potential prognostic biomarker in various diseases [8–13, 15, 16]. The gene discussed is GPT; the disease is viral hepatitis.